Emory University School of Medicine/Winship Cancer Institute Emory University Med School — Atlanta, Georgia

Emory University School of Medicine/Winship Cancer Institute Emory University Med School is a clinical research site located in Atlanta, Georgia, United States 30322.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Emory University School of Medicine/Winship Cancer Institute Emory University Med School has participated in 1 clinical trials.

Therapeutic areas: Hodgkin Lymphoma.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Emory University School of Medicine/Winship Cancer Institute Emory University Med School?

Emory University School of Medicine/Winship Cancer Institute Emory University Med School has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Emory University School of Medicine/Winship Cancer Institute Emory University Med School conducted?

Emory University School of Medicine/Winship Cancer Institute Emory University Med School has 1 clinical trials on record. Their work covers Hodgkin Lymphoma.

Is Emory University School of Medicine/Winship Cancer Institute Emory University Med School accredited by Crixeo Health?

Emory University School of Medicine/Winship Cancer Institute Emory University Med School has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Emory University School of Medicine/Winship Cancer Institute Emory University Med School?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.